Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Status unconfirmed · Phase 1

Conditions studied: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

In brief

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.

Key facts

Study ID
NCT05546580
Run by
Oryzon Genomics S.A.
People needed
50
Starts
2022-11-14
Expected to finish
2025-11-30
Last updated by the study team
2024-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.